Fremanezumab autoinjector pen for the prevention of migraine.

Abstract

Ajovy (fremanezumab, Teva Pharmaceuticals, Israel) is a fully humanized monoclonal antibody that selectively binds both isoforms of the calcitonin gene-related peptide. Calcitonin gene-related peptide is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events in migraine. It is indicated for prophylaxis of migraine in adults who have at least four migraine days per month, and can be administered as a subcutaneous injection using an autoinjector device, with two dosing options: 225 mg once a month or 675 mg quarterly. In this article, I present data from Phase III clinical trials of fremanezumab in episodic and chronic migraine, in which fremanezumab demonstrated efficacy and had a favorable tolerability profile, with no serious treatment-related adverse events.

• Authors: Mark W Weatherall
• Journal: Therapeutic delivery (Ther Deliv) Vol. 12 Issue 9 Pg. 645-650 (09 2021) ISSN: 2041-6008 [Electronic] England
• PMID: 34392708 (Publication Type: Clinical Trial, Phase III, Journal Article)

Chemical References

• Antibodies, Monoclonal
• fremanezumab
• Calcitonin Gene-Related Peptide

Topics

• Adult
• Antibodies, Monoclonal
• Calcitonin Gene-Related Peptide
• Double-Blind Method
• Humans
• Migraine Disorders (drug therapy, prevention & control)